Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors

Gregory L. Powell, John Paul Bonadonna, Annika Vannan, Kuiying Xu, Robert H. Mach, Robert T. Luedtke, Janet L. Neisewander

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Aims: The dopamine D3 receptor (D3R) is a pharmacotherapeutic target for drug dependence. We have successfully imaged human D3Rs using radiolabeled LS-3-134, an arylamide phenylpiperazine with moderate selectivity for the D3R over D2R and low efficacy at the D2 and D3R. In this study, we screened for effects of LS-3-134 as a potential anti-cocaine therapeutic. Methods: Male rats were pretreated with LS-3-134 (0, 1.0, 3.2, or 5.6 mg/kg, IP) 15 min prior to tests for its effects on spontaneous and cocaine-induced locomotion. We next investigated the effects of LS-3-134 (0, 1.0, 3.2, 5.6, or 10.0 mg/kg, IP) on operant responding on a multiple variable-interval (VI) 60-second schedule with alternating cocaine (0.375 mg/kg, IV) and sucrose (45 mg) reinforcer components. Additionally, we tested LS-3-134 (5.6 mg/kg, IP) effects on a progressive ratio (PR) schedule of cocaine reinforcement, on extinction of cocaine-seeking behavior, and on reinstatement of extinguished cocaine-seeking behavior by cocaine-associated light/tone cues. Results: LS-3-134 did not alter spontaneous locomotion, but reduced cocaine-induced locomotion, break points on the high-effort progressive ratio schedule of reinforcement, and responding during extinction and cue reinstatement. In contrast, LS-3-134 did not alter cocaine or sucrose reinforcement on the low-effort multiple VI 60-second schedule. Conclusions: The effects of LS-3-134 are similar to other dopamine D3 low efficacy partial agonists and antagonists in attenuating cocaine intake under high effort schedules of reinforcement and in attenuating cocaine-seeking behavior elicited by cocaine-associated cues. These findings are consistent with the anti-craving profile of other dopamine D3 drugs.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalPharmacology Biochemistry and Behavior
Volume175
DOIs
StatePublished - 1 Dec 2018

Fingerprint

Dopamine D3 Receptors
Cocaine
Reinforcement Schedule
Reinforcement
Locomotion
Cues
Sucrose
N-((4-(4-(2-(2-fluoroethoxy)phenyl)-1-piperazinyl)butyl)-4-(3-thienyl)benzamide
Dopamine
Appointments and Schedules
Dopamine Agents
Pharmaceutical Preparations
Substance-Related Disorders
Rats

Keywords

  • Cocaine-seeking behavior
  • Extinction
  • Phenylpiperazine
  • Progressive ratio
  • Reinforcement (psychology)
  • Reinstatement
  • Substance use disorders

Cite this

Powell, Gregory L. ; Bonadonna, John Paul ; Vannan, Annika ; Xu, Kuiying ; Mach, Robert H. ; Luedtke, Robert T. ; Neisewander, Janet L. / Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. In: Pharmacology Biochemistry and Behavior. 2018 ; Vol. 175. pp. 123-129.
@article{959c0e99a41e4cbcac8f5321572b6903,
title = "Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors",
abstract = "Aims: The dopamine D3 receptor (D3R) is a pharmacotherapeutic target for drug dependence. We have successfully imaged human D3Rs using radiolabeled LS-3-134, an arylamide phenylpiperazine with moderate selectivity for the D3R over D2R and low efficacy at the D2 and D3R. In this study, we screened for effects of LS-3-134 as a potential anti-cocaine therapeutic. Methods: Male rats were pretreated with LS-3-134 (0, 1.0, 3.2, or 5.6 mg/kg, IP) 15 min prior to tests for its effects on spontaneous and cocaine-induced locomotion. We next investigated the effects of LS-3-134 (0, 1.0, 3.2, 5.6, or 10.0 mg/kg, IP) on operant responding on a multiple variable-interval (VI) 60-second schedule with alternating cocaine (0.375 mg/kg, IV) and sucrose (45 mg) reinforcer components. Additionally, we tested LS-3-134 (5.6 mg/kg, IP) effects on a progressive ratio (PR) schedule of cocaine reinforcement, on extinction of cocaine-seeking behavior, and on reinstatement of extinguished cocaine-seeking behavior by cocaine-associated light/tone cues. Results: LS-3-134 did not alter spontaneous locomotion, but reduced cocaine-induced locomotion, break points on the high-effort progressive ratio schedule of reinforcement, and responding during extinction and cue reinstatement. In contrast, LS-3-134 did not alter cocaine or sucrose reinforcement on the low-effort multiple VI 60-second schedule. Conclusions: The effects of LS-3-134 are similar to other dopamine D3 low efficacy partial agonists and antagonists in attenuating cocaine intake under high effort schedules of reinforcement and in attenuating cocaine-seeking behavior elicited by cocaine-associated cues. These findings are consistent with the anti-craving profile of other dopamine D3 drugs.",
keywords = "Cocaine-seeking behavior, Extinction, Phenylpiperazine, Progressive ratio, Reinforcement (psychology), Reinstatement, Substance use disorders",
author = "Powell, {Gregory L.} and Bonadonna, {John Paul} and Annika Vannan and Kuiying Xu and Mach, {Robert H.} and Luedtke, {Robert T.} and Neisewander, {Janet L.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.pbb.2018.10.002",
language = "English",
volume = "175",
pages = "123--129",
journal = "Pharmacology, Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors. / Powell, Gregory L.; Bonadonna, John Paul; Vannan, Annika; Xu, Kuiying; Mach, Robert H.; Luedtke, Robert T.; Neisewander, Janet L.

In: Pharmacology Biochemistry and Behavior, Vol. 175, 01.12.2018, p. 123-129.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors

AU - Powell, Gregory L.

AU - Bonadonna, John Paul

AU - Vannan, Annika

AU - Xu, Kuiying

AU - Mach, Robert H.

AU - Luedtke, Robert T.

AU - Neisewander, Janet L.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Aims: The dopamine D3 receptor (D3R) is a pharmacotherapeutic target for drug dependence. We have successfully imaged human D3Rs using radiolabeled LS-3-134, an arylamide phenylpiperazine with moderate selectivity for the D3R over D2R and low efficacy at the D2 and D3R. In this study, we screened for effects of LS-3-134 as a potential anti-cocaine therapeutic. Methods: Male rats were pretreated with LS-3-134 (0, 1.0, 3.2, or 5.6 mg/kg, IP) 15 min prior to tests for its effects on spontaneous and cocaine-induced locomotion. We next investigated the effects of LS-3-134 (0, 1.0, 3.2, 5.6, or 10.0 mg/kg, IP) on operant responding on a multiple variable-interval (VI) 60-second schedule with alternating cocaine (0.375 mg/kg, IV) and sucrose (45 mg) reinforcer components. Additionally, we tested LS-3-134 (5.6 mg/kg, IP) effects on a progressive ratio (PR) schedule of cocaine reinforcement, on extinction of cocaine-seeking behavior, and on reinstatement of extinguished cocaine-seeking behavior by cocaine-associated light/tone cues. Results: LS-3-134 did not alter spontaneous locomotion, but reduced cocaine-induced locomotion, break points on the high-effort progressive ratio schedule of reinforcement, and responding during extinction and cue reinstatement. In contrast, LS-3-134 did not alter cocaine or sucrose reinforcement on the low-effort multiple VI 60-second schedule. Conclusions: The effects of LS-3-134 are similar to other dopamine D3 low efficacy partial agonists and antagonists in attenuating cocaine intake under high effort schedules of reinforcement and in attenuating cocaine-seeking behavior elicited by cocaine-associated cues. These findings are consistent with the anti-craving profile of other dopamine D3 drugs.

AB - Aims: The dopamine D3 receptor (D3R) is a pharmacotherapeutic target for drug dependence. We have successfully imaged human D3Rs using radiolabeled LS-3-134, an arylamide phenylpiperazine with moderate selectivity for the D3R over D2R and low efficacy at the D2 and D3R. In this study, we screened for effects of LS-3-134 as a potential anti-cocaine therapeutic. Methods: Male rats were pretreated with LS-3-134 (0, 1.0, 3.2, or 5.6 mg/kg, IP) 15 min prior to tests for its effects on spontaneous and cocaine-induced locomotion. We next investigated the effects of LS-3-134 (0, 1.0, 3.2, 5.6, or 10.0 mg/kg, IP) on operant responding on a multiple variable-interval (VI) 60-second schedule with alternating cocaine (0.375 mg/kg, IV) and sucrose (45 mg) reinforcer components. Additionally, we tested LS-3-134 (5.6 mg/kg, IP) effects on a progressive ratio (PR) schedule of cocaine reinforcement, on extinction of cocaine-seeking behavior, and on reinstatement of extinguished cocaine-seeking behavior by cocaine-associated light/tone cues. Results: LS-3-134 did not alter spontaneous locomotion, but reduced cocaine-induced locomotion, break points on the high-effort progressive ratio schedule of reinforcement, and responding during extinction and cue reinstatement. In contrast, LS-3-134 did not alter cocaine or sucrose reinforcement on the low-effort multiple VI 60-second schedule. Conclusions: The effects of LS-3-134 are similar to other dopamine D3 low efficacy partial agonists and antagonists in attenuating cocaine intake under high effort schedules of reinforcement and in attenuating cocaine-seeking behavior elicited by cocaine-associated cues. These findings are consistent with the anti-craving profile of other dopamine D3 drugs.

KW - Cocaine-seeking behavior

KW - Extinction

KW - Phenylpiperazine

KW - Progressive ratio

KW - Reinforcement (psychology)

KW - Reinstatement

KW - Substance use disorders

UR - http://www.scopus.com/inward/record.url?scp=85055052496&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2018.10.002

DO - 10.1016/j.pbb.2018.10.002

M3 - Article

VL - 175

SP - 123

EP - 129

JO - Pharmacology, Biochemistry and Behavior

JF - Pharmacology, Biochemistry and Behavior

SN - 0091-3057

ER -